IMPDH2 and prostate cancer: Importantly, candidate proteins, IMPDH2, HNRNPK, OXCT1, ACPP, and LDHB, were highly expressed in progressive prostate cancer patients (Figure 6d, and the elevated expression of TUFM, HNRNPH3, and CCT2 was significantly associated with progression-free interval in prostate cancer patients diagnosed with a Gleason Score 6 or higher (Figure 6b, supporting the inference that the identified proteins might contribute to prostate cancer progression.